Adrienne Graves

Alcon Laboratories, Inc. develops and manufactures ophthalmic pharmaceutical products. The firm offers over-the-counter eye care products, medical devices, equipment, ophthalmic drugs, surgical instruments, needles, and sutures for microsurgery and disposable drapes. The company was founded by Robert Alexander and William Conner in 1945 and is headquartered in Fort Worth, TX.

The Foundation Fighting Blindness, Inc. provides preventions, treatments and cures for people affected by retinitis pigmentosa, macular degeneration and usher syndrome. The firm also provides provide information on retinal degenerative diseases to all who request it, in order to increase knowledge and awareness of these diseases. It has locations in Columbia, Denver, Libertyville, New York, Plano, Raleigh and Santa Monica. The company was founded on September 16, 1971 and is headquartered in Columbia, MD.

Part of Santen Pharmaceutical Co., Ltd., Santen, Inc. is a company that develops ophthalmic products. The company is based in Emeryville, CA. The company was founded in 1993 by Adrienne L. Graves. Tatsuya Kaihara has been the CEO of the company since 2017.

The Association for Research in Vision & Ophthalmology operates an association focused on research in vision and ophthalmology. The non-profit company is based in Rockville, MD.

American Academy of Ophthalmology, Inc. is the world's largest association of eye physicians and surgeons. The non-profit company is based in San Francisco, CA, and has subsidiaries in the United States. The company advocates for patients and the public and set standards for ophthalmic education. The organization provides information about managing a practice, clinical pearls, and how to thrive in residency for young ophthalmologists. The company also offers an Outstanding Humanitarian Service Award and have committees that are essential to the establishment and implementation of the organization's mission and strategic goals. The Academy's website, EyeSmart, provides information on eye diseases, treatments, news, and tips for lifelong eye health. The company also has a faculty development program for their annual meeting and offer a program called Eyecelerator that advances eye care innovation by connecting creative entrepreneurs with mission-driven investors and access to markets.

The American Glaucoma Society supports glaucoma specialists and scientists through the advancement of education and research.

Women in Ophthalmology, Inc. provides support to ophthalmologists. It offers professional development, carrier advancement, and interactive networking to its members. The company is headquartered in Denver, CO.

IVERIC bio, Inc. operates as a biopharmaceutical company. The firm engages in discovering, developing and commercializing novel therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. Its product candidates include Zimura and Gene Therapy. The company was founded by David R. Guyer and Samir Chandrakant Patel on January 5, 2007 and is headquartered in Parsippany, NJ.

Glaucoma Research Foundation provides education services. The non-profit company is based in San Francisco, CA. The company was founded by Adrienne L. Graves. The CEO is Thomas M. Brunner.

Implandata Ophthalmic Products GmbH develops diagnosis tool for glaucoma therapy. Its technology Pro-IOP is an eye pressure measurement system consists of an implantable micro sensor, responsible for pressure sensing, an external hand held device, which is transferring energy to the micro sensor telemetrically and which is responsible for data read out and storage and a GSM module which can be connected with the hand held device for transfer of measurement data to a database, which can be accessed by the eye doctor in order to get information about the disease status of the patient. The company was founded by Max Georg Ostermeier and Stefan Meyer in January 2010 and is headquartered in Hannover, Germany.

Encore Vision, Inc. operates as an ophthalmology clinic. It offers EV06, an ophthalmic pharmaceutical solution in a conventional eye drop bottle, which includes its proprietary active pharmaceutical ingredient (API). The company is headquartered in Spokane, WA.

Envisia Therapeutics, Inc. develops novel ocular therapies. It provides glaucoma drug therapies that include PRINT particle therapeutics to overcome biologic and chemical. The company was founded by 2013 is headquartered in Morrisville, NC.

Aerpio Pharmaceuticals Inc. is a biopharmaceutical company, which engages in the research and development of treatments for ocular diseases. The firm's product candidate is AKB-9778, a small molecule activator of the Tie2 pathway, which completed the Phase 2a clinical trial for the treatment of diabetic retinopathy. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications; and AKB-4924, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed a single ascending dose clinical trial for the treatment of inflammatory bowel disease. The company was founded by Joseph H. Garder on November 16, 2007 and is headquartered in Cincinnati, OH.

Surface Ophthalmics, Inc. operates as a biopharmaceutical company. It focuses on development and commercialization of innovative therapeutics. The firm’s current drug pipeline consists of three proprietary drug candidates. Surface topical eye drop drug candidates, SURF-100 and SURF-200, utilize a patented delivery vehicle. The company is founded by Mark L. Baum and it is headquartered in San Diego, CA.

Qlaris Bio, Inc. operates as a biotechnology company. The company was founded by Thurein Htoo and Barbara Wirostko and is headquartered in Wellesley, MA.

TherOptix, Inc. develops and manufactures drug-eluting contact lens. The company is headquartered in San Francisco, CA.

NVasc, Inc. is an early-stage ophthalmology company founded in February 2019 and funded by Kairos Ventures in November 2019. The company is based in Atherton, CA. The company is focused on treating the leading causes of blindness through choroidal and retinal revascularization. The company is planning to manufacture NVB001 that can be used in toxicokinetic studies and in early clinical trials in humans. NVasc has acquired the research rights to growth factors (NVB001 and NVB002) that have been shown to encourage the growth of non-leaking new vessels in the retina and choroid in mouse models of ischemic eye diseases.

Opus Genetics, Inc. is a gene therapy company that focuses on treating inherited retinal diseases. The company is based in Raleigh, NC, and leverages knowledge of the best science and the expertise of pioneers in ocular gene therapy to transparently drive transformative treatments to patients. The company has a unique model and purpose, and is backed by Foundation Fighting Blindness's venture arm, the RD Fund. Opus Genetics has wholly owned programs in numerous orphan retinal diseases, and its AAV-based gene therapy portfolio tackles some of the most neglected forms of inherited blindness while creating novel orphan manufacturing scale and efficiencies. The company was founded in 2021 by Benjamin R. Yerxa, Peter L. Ginsberg, Jason D. Menzo, Jean Bennett, Russell Kelley, Jean Bennett. Benjamin R. Yerxa has been the CEO since 2021.

KeepYourSight Foundation provides e-health initiative in the fight against blindness. The company is headquartered in united States.